Q2 2026 saw 48% revenue growth and 33% higher non-GAAP EPS, driven by strong incretin and key product sales. Updated 2026 guidance reflects robust demand, expanded access, and pipeline progress, with significant investments in R&D and acquisitions.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.